Equity Research Analysts at KeyBanc Reiterated their “Overweight” rating for At Home Group (HOME). The Target Price Given is $42; Idexx Laboratories (IDXX) Shorts Lowered By 5.91%

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Logo

Idexx Laboratories Inc (NASDAQ:IDXX) had a decrease of 5.91% in short interest. IDXX’s SI was 1.61M shares in May as released by FINRA. Its down 5.91% from 1.71 million shares previously. With 568,800 avg volume, 3 days are for Idexx Laboratories Inc (NASDAQ:IDXX)’s short sellers to cover IDXX’s short positions. The SI to Idexx Laboratories Inc’s float is 1.87%. The stock decreased 2.20% or $4.67 during the last trading session, reaching $207.53. About 753,744 shares traded or 47.21% up from the average. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 23.99% since May 8, 2017 and is uptrending. It has outperformed by 12.44% the S&P500.

Stock analysts at KeyBanc have $42 target price per share on At Home Group (HOME). KeyBanc’s target price per share would indicate a potential upside of 17.12% from the company’s last stock close. The rating was shown in a research note on 8 May.

More recent IDEXX Laboratories, Inc. (NASDAQ:IDXX) news were published by: Nasdaq.com which released: “Research Report Identifies Cara Therapeutics, MGE Energy, IDEXX Laboratories, Sterling Construction, TTM …” on April 30, 2018. Also Benzinga.com published the news titled: “Earnings Scheduled For May 4, 2018” on May 04, 2018. Seekingalpha.com‘s news article titled: “Walgreens Is A Buy – Cramer’s Lightning Round (4/26/18)” with publication date: April 27, 2018 was also an interesting one.

Among 11 analysts covering IDEXX Laboratories (NASDAQ:IDXX), 7 have Buy rating, 2 Sell and 2 Hold. Therefore 64% are positive. IDEXX Laboratories had 29 analyst reports since July 24, 2015 according to SRatingsIntel. The company was downgraded on Friday, August 28 by Raymond James. The rating was maintained by Credit Suisse on Wednesday, April 13 with “Outperform”. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, October 5. The firm has “Buy” rating given on Monday, May 7 by Stifel Nicolaus. On Friday, February 2 the stock rating was maintained by Bank of America with “Buy”. The rating was maintained by Canaccord Genuity on Monday, January 29 with “Buy”. The rating was maintained by Canaccord Genuity on Tuesday, June 13 with “Buy”. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, August 13 report. The rating was initiated by CL King with “Neutral” on Friday, April 1. On Friday, February 3 the stock rating was downgraded by Feltl & Co to “Sell”.

Investors sentiment decreased to 0.81 in Q4 2017. Its down 0.05, from 0.86 in 2017Q3. It is negative, as 30 investors sold IDEXX Laboratories, Inc. shares while 217 reduced holdings. 64 funds opened positions while 137 raised stakes. 72.13 million shares or 17.89% less from 87.85 million shares in 2017Q3 were reported. Tokio Marine Asset Management Ltd reported 5,500 shares or 0.13% of all its holdings. Qs Limited Liability holds 7,765 shares or 0.01% of its portfolio. Moreover, Schwab Charles Inv Mngmt has 0.04% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX). 6,910 were accumulated by Shelton Cap Mngmt. Moreover, Caisse De Depot Et Placement Du Quebec has 0% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Rmb Llc reported 27,651 shares. Morgan Stanley reported 311,977 shares. 656 were accumulated by First Personal Financial Serv. Sumitomo Mitsui Asset Ltd accumulated 0.01% or 6,142 shares. Utd Advisers Ltd Co holds 21,957 shares or 0.03% of its portfolio. 56 were reported by City. Hanson And Doremus Investment Mgmt holds 0.01% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 200 shares. Zacks Invest Management holds 0.02% or 7,053 shares in its portfolio. Dekabank Deutsche Girozentrale reported 19,090 shares. Moreover, Cardinal Capital Mgmt has 0.89% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Since January 9, 2018, it had 2 insider purchases, and 6 sales for $21.47 million activity. AYERS JONATHAN W sold $6.45M worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Monday, February 5. Claflin Bruce L. bought $179,580 worth of stock or 1,000 shares. $737,939 worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was sold by END WILLIAM T. MCKEON BRIAN P also sold $1.20 million worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) shares. 2,974 IDEXX Laboratories, Inc. (NASDAQ:IDXX) shares with value of $565,232 were sold by JUNIUS DANIEL M. Kingsley Lawrence D bought $178,045 worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Wednesday, February 14.

IDEXX Laboratories, Inc., together with its subsidiaries, develops, makes, and distributes services and products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company has market cap of $18.03 billion. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other divisions. It has a 70.59 P/E ratio. The firm provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assays; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.

Analysts await At Home Group Inc. (NYSE:HOME) to report earnings on June, 6. They expect $0.25 earnings per share, up 31.58% or $0.06 from last year’s $0.19 per share. HOME’s profit will be $15.41M for 35.86 P/E if the $0.25 EPS becomes a reality. After $0.41 actual earnings per share reported by At Home Group Inc. for the previous quarter, Wall Street now forecasts -39.02% negative EPS growth.

Among 9 analysts covering At Home Group (HOME), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. At Home Group has $43 highest and $17.0 lowest target. $33.25’s average target is -7.28% below currents $35.86 stock price. At Home Group had 14 analyst reports since August 29, 2016 according to SRatingsIntel. On Wednesday, December 20 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. The stock has “Buy” rating by Jefferies on Monday, August 29. Tigress Financial initiated the stock with “Buy” rating in Tuesday, September 13 report. Guggenheim maintained At Home Group Inc. (NYSE:HOME) on Thursday, December 21 with “Buy” rating. Goldman Sachs upgraded it to “Buy” rating and $19 target in Wednesday, November 30 report. On Thursday, January 25 the stock rating was initiated by Barclays Capital with “Buy”. The stock of At Home Group Inc. (NYSE:HOME) earned “Buy” rating by Jefferies on Thursday, November 30. The stock has “Buy” rating by Guggenheim on Wednesday, September 14. The stock of At Home Group Inc. (NYSE:HOME) has “Neutral” rating given on Monday, August 29 by Guggenheim. The company was initiated on Tuesday, August 30 by Morgan Stanley.

The stock decreased 2.63% or $0.97 during the last trading session, reaching $35.86. About 231,123 shares traded. At Home Group Inc. (HOME) has risen 95.65% since May 8, 2017 and is uptrending. It has outperformed by 84.10% the S&P500.

At Home Group Inc. operates home decor superstores in the United States. The company has market cap of $2.21 billion. The company’s stores offer approximately 50,000 items, such as accent furniture, frames, pottery, bar stools, garden décor, rugs and mats, bedding and bath products, Halloween decorations, sculptures, beds and mattresses, harvest decorations, silk flowers, candles, home organization products, sofas, chairs, kitchenware, stands, Christmas decorations, lamps, storage products, consumables, mirrors, tables, Easter decorations, patio products, vases, floor plants and trees, pet items, wall arts, food preparation items, pillows and cushions, and window treatments. It has a 71.72 P/E ratio. As of September 13, 2017, it operated 141 stores in 33 states.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Institutional Positions Chart